The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Adjuvant Therapy for Melanoma: Who, What, When?
September 28th 2018More patients than ever before may now be good candidates for adjuvant therapy and derive long-term benefits from it, but new data and expanding treatment options have led to many new questions on how to optimize treatment for melanoma.
Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma
September 22nd 2018Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma
FDA Grants Pembrolizumab Priority Review for Merkel Cell Carcinoma
September 4th 2018The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for the treatment of pediatric and adult patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade
September 4th 2018Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.
Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma
August 31st 2018Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.
Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma
August 31st 2018Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.
Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma
July 31st 2018Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.
Adjuvant Dabrafenib/Trametinib Nears European Approval for BRAF+ Melanoma
July 27th 2018The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of dabrafenib and trametinib for the adjuvant treatment of adult patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.
Binimetinib/Encorafenib Combo Approaches European Approval for BRAF+ Melanoma
July 27th 2018The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.
Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab
July 20th 2018Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.
EU Panel Backs Adjuvant Nivolumab for Melanoma
June 29th 2018The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease
Dr. Postow on the FDA Approval of Encorafenib and Binimetinib in BRAF-Mutant Melanoma
June 27th 2018Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of encorafenib plus binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.
FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma
June 27th 2018The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.